TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile

When do Travasol 4.25% In Dextrose 5% In Plastic Container patents expire, and what generic alternatives are available?

Travasol 4.25% In Dextrose 5% In Plastic Container is a drug marketed by Baxter Hlthcare and is included in two NDAs.

The generic ingredient in TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER is amino acids; dextrose; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride. There are three hundred and fifty drug master file entries for this compound. Additional details are available on the amino acids; dextrose; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride profile page.

Summary for TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	2
Clinical Trials:	2
DailyMed Link:	TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Canadian Institutes of Health Research (CIHR)	Phase 4
McGill University Health Centre/Research Institute of the McGill University Health Centre	Phase 4
McGill University Health Center	Phase 4

See all TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER clinical trials

US Patents and Regulatory Information for TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER	amino acids; dextrose	INJECTABLE;INJECTION	019520-006	Sep 23, 1988		DISCN	No	No
Baxter Hlthcare	TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER	amino acids; dextrose; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride	INJECTABLE;INJECTION	020147-006	Oct 23, 1995		DISCN	No	No

Market Dynamics and Financial Trajectory for Travasol 4.25% in Dextrose

Introduction

Travasol 4.25% in Dextrose is a formulation of amino acid injection, often used in clinical settings for parenteral nutrition. To understand its market dynamics and financial trajectory, we need to delve into several key aspects, including its composition, regulatory status, market competition, and the financial performance of the companies involved.

Composition and Clinical Use

Travasol is an amino acid injection that comes in various concentrations and formulations, including those with dextrose. The 4.25% amino acid solution in 5% or 20% dextrose is designed to provide essential amino acids and carbohydrates for patients requiring intravenous nutrition[4].

Regulatory Status

The regulatory status of Travasol products can be complex, with various formulations having different approval and market statuses. For instance, some Travasol products have been cancelled post-market, indicating changes in regulatory approval or market availability[4].

Market Competition

The market for parenteral nutrition products is competitive, with several companies offering similar formulations. Baxter Corporation, through its Clinitec Nutrition Division, has been a significant player in this market, although some of its Travasol products have been cancelled post-market[4].

Financial Trajectory of Related Companies

Baxter Corporation

While specific financial data for Travasol 4.25% in Dextrose is not readily available, we can look at the broader financial context of companies involved in parenteral nutrition.

Baxter Corporation, a major player in this market, has experienced fluctuations in its financial performance. However, the specific financial trajectory of Travasol products is not detailed in recent financial reports, as these reports typically aggregate data across various product lines.

Travere Therapeutics: A Comparative Analysis

Although Travere Therapeutics is not directly involved in the production of Travasol, analyzing its financial performance can provide insights into the broader pharmaceutical and biotech industry trends.

Travere Therapeutics has seen significant growth in its net product sales, particularly with the launch of FILSPARI (sparsentan) for IgA Nephropathy (IgAN). For the third quarter of 2024, net product sales of FILSPARI totaled $35.6 million, contributing to a total revenue of $62.9 million for the quarter[2][5].

Key Financial Metrics

• Net Product Sales: For companies like Travere Therapeutics, net product sales are a critical metric. While Travasol products do not have specific sales data available, the success of other pharmaceutical products indicates a growing demand for specialized clinical nutrition solutions.
• Research and Development (R&D) Expenses: Companies in the pharmaceutical and biotech sectors often have high R&D expenses. For Travere Therapeutics, R&D expenses for the third quarter of 2024 were $51.7 million, reflecting ongoing investment in product development[2][5].
• Selling, General, and Administrative (SG&A) Expenses: These expenses are crucial for understanding the operational efficiency of a company. For Travere Therapeutics, SG&A expenses for the third quarter of 2024 were $65.6 million, showing a slight decrease from the previous year due to restructuring and cost-saving initiatives[2][5].

Market Trends and Outlook

• Growing Demand for Parenteral Nutrition: The demand for parenteral nutrition solutions is increasing due to the rising need for clinical nutrition in hospitals and healthcare settings.
• Regulatory Changes: Changes in regulatory approvals and post-market cancellations can significantly impact the market dynamics of specific products like Travasol.
• Innovation and Competition: The market is driven by innovation, with companies continually developing new formulations and delivery systems to meet clinical needs.

Challenges and Opportunities

• Regulatory Hurdles: Products like Travasol face stringent regulatory requirements, and any changes in these regulations can affect their market availability.
• Market Competition: The competitive landscape in parenteral nutrition is intense, with multiple players offering similar products.
• Innovation: Companies that innovate and adapt to clinical needs can capture significant market share.

Conclusion

The market dynamics and financial trajectory for Travasol 4.25% in Dextrose are influenced by broader trends in the pharmaceutical and biotech industries. While specific financial data for this product is limited, analyzing the performance of related companies and understanding market trends provides valuable insights.

Key Takeaways

• Regulatory Status: Travasol products have experienced post-market cancellations, affecting their availability.
• Market Competition: The parenteral nutrition market is highly competitive.
• Financial Performance: Companies in this sector often have high R&D and SG&A expenses.
• Growing Demand: There is an increasing demand for specialized clinical nutrition solutions.
• Innovation: Innovation is key to capturing market share in this competitive landscape.

FAQs

1. What is Travasol 4.25% in Dextrose used for?

   • Travasol 4.25% in Dextrose is used for parenteral nutrition, providing essential amino acids and carbohydrates to patients.

2. Which company produces Travasol?

   • Travasol is produced by Baxter Corporation through its Clinitec Nutrition Division.

3. What is the current regulatory status of Travasol products?

   • Some Travasol products have been cancelled post-market, indicating changes in regulatory approval or market availability.

4. How does the financial performance of Travere Therapeutics relate to Travasol?

   • While Travere Therapeutics is not directly involved in Travasol, its financial performance in the pharmaceutical sector provides insights into industry trends.

5. What are the key challenges for Travasol in the market?

   • Regulatory hurdles, market competition, and the need for innovation are significant challenges for Travasol and similar products.

Cited Sources

1. PharmaCompass - Certificates of Suitability (CEP/COS) of TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER-1 API[1].
2. GlobeNewswire - Travere Therapeutics Reports Third Quarter 2024 Financial Results[2].
3. Travere Therapeutics - Travere Therapeutics Reports First Quarter 2024 Financial Results[3].
4. Health Products, Canada.ca - Search results summary for Travasol products[4].
5. Travere Therapeutics - Travere Therapeutics Reports Third Quarter 2024 Financial Results[5].